Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

(NasdaqGM:ETON), Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million Launched KHINDIVI(TM) (hydrocortisone) Oral Solution Reached 100 active INCRELEX(R) […]

Bridger Aerospace Announces Strongest Second Quarter in Company History

(NasdaqGM:BAER),(NasdaqGM:BAERW), BELGRADE, Mont., Aug. 07, 2025 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation's largest aerial firefighting companies, today reported record results for the second quarter ended June 30, 2025. Second Quarter Highlights: Record-setting revenue of $30.8 million, more than double last

AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation

(AUST:AVH.AX),(NASDAQ:RCEL), VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Results Commercial revenue of $18.4 million: Representing an increase of approximately 21% compared to the same

Karat Packaging Reports 2025 Second Quarter Financial Results

(NASDAQ:KRT), — Record Quarterly Net Sales and Net Income — — Successful Alternative Sourcing to Navigate Tariff Uncertainty — CHINO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for

Allbirds Reports Second Quarter 2025 Financial Results

Allbirds Reports Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 Delivers Second Quarter Results in Line with and Above Guidance Ranges Revises Full Year 2025 Revenue Outlook and Reiterates Adjusted EBITDA Guidance Product, Marketing and Customer Experience Initiatives Expected to Fuel Revenue Growth in Q4 2025 SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) —

Full House Resorts Announces Second Quarter Results

Full House Resorts Announces Second Quarter Results GlobeNewswire August 07, 2025 – American Place Casino Continued Its Strong Growth, Achieving Record Net Revenue and Operating Profit – Colorado Operations Reported a 7.8% Increase in Revenue Compared to the Prior-Year Period – Revamped Marketing Efforts at Chamonix Began in the Third Quarter; Focused Cost Reductions at

Westrock Coffee Company Reports Second Quarter 2025 Results and Reaffirms 2025 and 2026 Outlook

(NasdaqGM:WEST), LITTLE ROCK, Ark., Aug. 07, 2025 (GLOBE NEWSWIRE) — Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or the “Company”) today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights(1) Consolidated Results Net sales were $280.9 million, an increase of 34.8% Gross profit was $41.4 million, flat compared to the

IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery GlobeNewswire August 07, 2025 Project will leverage Ignite Proteomics' reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK),

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA)

The Joint Corp. Reports Second Quarter 2025 Financial Results

The Joint Corp. Reports Second Quarter 2025 Financial Results GlobeNewswire August 07, 2025 – Refranchised 37 clinics; Franchises now represent 92% of the portfolio – – Acquired rights to the Northwest regional developer territory – SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of

Scroll to Top